Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo
Source abstract
Abstract
Wear debris-induced vascularized granulomatous periprosthetic tissue may augment the progress of prosthetic loosening, a major clinical problem after total joint replacement. The purpose of this study is to investigate the association of ultra-high-molecular-weight polyethylene (UHMWPE) particle-induced inflammatory osteoclastogenesis and expression of RANK/RANKL and VEGF/VEGF receptors (Flt-1 and Flk-1) using a mouse osteolysis model. UHMWPE particles were introduced into established air pouches on BALB/c mice, followed by implantation of calvaria bone from syngeneic littermates. Mice were injected with either recombinant VEGF or VEGF inhibitor (VEGF R2/F(c) Chimera). Mice without drug treatment, as well as mice injected with saline alone were included. Each group contains 10 mice. Pouch tissues were harvested 2 weeks after bone implantation for histological and molecular analysis. UHMWPE stimulation significantly increased VEGF gene expression, and exerted a lower enhancement effect on the gene expression of Flt-1 and Flk-1. UHMWPE-stimulated VEGF production was markedly reduced by VEGF inhibitor treatment. Immunofluorescent staining indicated that pouch tissue macrophages were the main source of both VEGF and Flt-1 production. A positive association was observed between tissue inflammation and the levels of VEGF and Flt-1 gene transcripts. Both RANK and RANKL gene transcripts were significantly increased by UHMWPE stimulation, which was subsequently reduced by VEGF inhibitor treatment (p<0.05). VEGF treatment increased TRAP(+) cells in pouches either with or without UHMWPE particle stimulation, and VEGF inhibitor treatment caused a significant reduction in the number of TRAP(+) cells in UHMWPE-containing pouches. This study suggests that VEGF has a role in the regulation of RANK/RANKL-mediated osteoclastogenesis, and warrant future investigations to elucidate the role of VEGF signaling in the pathogenesis of prosthetic loosening.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Orthopaedic implants and arthroplasty · Bone and Joint Diseases · Bone Metabolism and Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants10.1136/ard.54.3.201 ↗
2. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles10.1359/jbmr.2003.18.9.1573 ↗
3. The molecular perspective: VEGF and angiogenesis10.1634/theoncologist.7-6-569 ↗
4. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis10.1002/bdrc.10024 ↗
5. The biology of vascular endothelial growth factor10.1210/edrv.18.1.0287 ↗
6. Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone10.1016/j.bbrc.2004.02.076 ↗
7. Upregulation of vascular endothelial growth factor (VEGF) in the retinas of transgenic mice overexpressing interleukin-1beta (IL-1beta) in the lens and mice undergoing retinal degeneration
8. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor10.1016/S0021-9258(18)47116-5 ↗
9. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans10.1182/blood.V97.3.785 ↗
10. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-110.1182/blood.V87.8.3336.bloodjournal8783336 ↗
11. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils10.1165/rcmb.2003-0314OC ↗
12. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor10.1182/blood-2002-11-3423 ↗
13. Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints10.4049/jimmunol.168.11.5824 ↗
14. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption10.1084/jem.190.2.293 ↗
15. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts10.1016/S0014-5793(00)01520-9 ↗
16. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand10.1074/jbc.M300539200 ↗
17. Minireview: the OPG/RANKL/RANK system10.1210/endo.142.12.8536 ↗
18. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis10.1006/bbrc.1998.9788 ↗
19. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism10.1073/pnas.97.4.1566 ↗
20. Effects of vascular endothelial growth factor on osteoclast induction during tooth movement in mice10.1177/00220345010800100401 ↗
21. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones10.1083/jcb.151.4.879 ↗
22. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism10.1074/jbc.M309193200 ↗
23. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model10.1053/jhep.2000.20521 ↗
24. A novel murine model of orthopaedic wear debris-associated osteolysis10.1080/03009740410005944 ↗
25. Inflammatory responses to orthopaedic biomaterials in the murine air pouch10.1016/S0142-9612(01)00134-X ↗
26. Polyethylene and methyl methacrylate particle-stimulated inflammatory tissue and macrophages up-regulate bone resorption in a murine neonatal bone resorption in a murine neonatal calvaria in vitro organ system10.1016/S0736-0266(02)00019-0 ↗
27. Diverse cellular and apoptotic responses to variant shapes of UHMWPE particles in a murine model of inflammation10.1016/S0142-9612(02)00032-7 ↗
28. RANK is essential for osteoclast and lymph node development10.1101/gad.13.18.2412 ↗
29. Distinct gene expression of receptor activator of nuclear factor-kB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles10.1016/S0142-9612(03)00384-3 ↗
30. Inflammation and angiogenesis in osteoarthritis10.1002/art.11094 ↗
31. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis10.1002/1096-9896(2000)9999:9999<::AID-PATH649>3.0.CO;2-E ↗
32. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue10.1084/jem.180.1.341 ↗
33. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders10.1111/j.1749-6632.2002.tb04870.x ↗
34. Does a pro-angiogenic state exist in the bone-implant interface of aseptically loosened joint prosthesis?
35. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis10.4049/jimmunol.171.9.4853 ↗
36. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism10.1530/eje.0.1410195 ↗
37. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?]
38. Bone loss: factors that regulate osteoclast differentiation: an update10.1186/ar127 ↗